Completed

CELADENCelgosivir Proof of Concept Trial for Treatment of Acute Dengue Fever

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

celgosivir

+ placebo

Drug
Who is being recruted

Vector Borne Diseases+7

+ Mosquito-Borne Diseases

+ Arbovirus Infections

From 21 to 60 Years
+10 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Treatment Study

Placebo-ControlledPhase 1 & 2
Interventional
Study Start: July 2012
See protocol details

Summary

Principal SponsorSingapore General Hospital
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: July 1, 2012

Actual date on which the first participant was enrolled.

Patients with confirmed dengue fever who meet all inclusion and exclusion criteria will be enrolled and admitted to the Investigational Medicine Unit. Patients will be randomized 1:1 to celgosivir or placebo. Capsules of placebo or celgosivir will be administered for 5 days. While in hospital, daily clinical exams will be conducted, and blood samples will be collected for viral load, quantitative NS1, hematology, clinical chemistry, cytokine levels and pharmacokinetics (PK). Safety assessments will be conducted. At discharge on Study Day 5, patients will be asked to return on Study Days 7, 10, and 15 for blood sampling and safety assessments.

Official TitleCelgosivir Proof of Concept Trial for Treatment of Acute Dengue Fever
NCT01619969
Principal SponsorSingapore General Hospital
Last updated: January 27, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

50 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 21 to 60 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Vector Borne DiseasesMosquito-Borne DiseasesArbovirus InfectionsDengueHemorrhagic Fevers, ViralInfectionsRNA Virus InfectionsVirus DiseasesFlavivirus InfectionsFlaviviridae Infections

Criteria

10 exclusion criteria prevent from participating
Clinical signs and symptoms for severe dengue
Patients with certain abnormal laboratory values
History of presently active intestinal disorders
Severe diarrhea
Show More Criteria

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

2 intervention groups are designated in this study

50% chance of being blinded to the placebo group

Treatment Groups

Group I

Experimental

Group II

Placebo

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Suspended

Singapore General Hospital

Singapore, SingaporeOpen Singapore General Hospital in Google Maps
CompletedOne Study Center